2Turkkabraman D, Bircan I, Tribble ND, Akqurin S, Ellard S,Gloyn AL. Permanent neonatal diabetes mellitus caused by a novel homozyous(T168A) glucokinase(GCK) mutation : initial response to oral sulphonylurea therapy[ J]. J Pediatr, 2008, 153 ( 1 ) : 122- 126.
3Polak M, Dechaume A, Care H, Nimri R, Crosnier H, Sulmont V, et al. Heterozygotts missense mutations in the insulin gene are linked to permanent diabetes appearing in the neonatal period or in early infancy: a report from the French ND (Neonatal Diabetes) Study Group[J]. Diabetes, 2008, 57(4) : 1115-1119.
4Care H, Polak M, Drunat S, Denamur E, Czernichow P. Refinement of the 6q chromosomal region implicated in transient neonatal diabetes [ J ]. Diabetes, 2000, 49 ( 1 ) : 108-113.
5Flanagan SE, Patch AM, Mackay DJ, Edghill EL, Gloyn AL, Robinson D, et al. Mutation in ATP-sensitive K^+ channel genes cause transient neonatal diabetes and permanent diabetes in childhood or adultdhood [ J ]. Diabetes, 2007, 56 (7) : 1930-1937.
6De Leon DD, Stanley CA. Permanent neonatal diabetes mellitus [ DB/OL ]. [ 2008-02-08 ]. http://www, nebi. nlm. nim. gov/ books/NBK1447/.
7Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues [ J ]. Diabetes, 2004, 53 ( Suppl 3 ) : S48-S58.
8Proks P, Girard C, Haider S, Gloyn AL, Hattersley AT, Sansom MS, et al. A gating mutation at the internal mouth of the Kir 6.2 pore is associated with DEND syndrome[ J]. EMBO Rep, 2005,6 (5) : 470-475.
9Gloyn AL, Diatloff-Zito C, Edghill EL, Bellannc-Chantelot C, Nivot S, Coutant R,et al. KCNJI 1 activating mutation are associated with developmental delay, epilepsy and neonatal diabetes syndrome and other neurological features [ J ]. Eur J Hum Genet, 2006, 14(7): 824-830.
10Slingerland AS, Hurkx W, Noordam K, Flanagan SE, Jukema JW, Meiners LC, et al. Sulphonylurea therapy improve cognition in a patient with the V59M KCNJll mutation [ J ]. Diabet Med, 2008, 25(3) : 277-28l.
